Clinical
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
The randomized phase 3 HERON-Lung01 trial evaluated the efficacy and safety of ruzaltatug rezetecan, a novel HER3-directed antibody-drug conjugate (ADC), compared with platinum-pemetrexed chemotherapy in 498 patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who progressed on prior EGFR tyrosine kinase inhibitor (TKI) therapy. At the prespecified interim analysis, ruzaltatug rezetecan significantly prolonged progression-free survival compared to chemotherapy (median 8.3 months vs 5.4 months; HR 0.47; p < 0.0001). The safety profile was manageable, with grade 3 or higher treatment-related adverse events occurring in 41% vs 39% of patients, predominantly hematological, and leading to treatment discontinuation in only 1% per arm. These findings establish ruzaltatug rezetecan as a promising post-TKI therapeutic option in advanced EGFR-mutated NSCLC.